GBIM:OTCMKTS
GlobeImmune Inc
$0.00010
0.00%
(0.00) 1D
Sep 29, 3:48:52 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBIM...
Mkt. cap
580.00
Avg. vol.
1.74K
Volume
0.00
52-wk high
$0.04
52-wk low
$0.00
Shares outstanding
5.75M
No. of employees
22
Mkt. cap
580.00
Avg. vol.
1.74K
Volume
0.00
52-wk high
$0.04
52-wk low
$0.00
Shares outstanding
5.75M
No. of employees
22
News stories
From web sources and news partners
24/7 Wall St.
·
21 minutes ago
Western Digital Crushed the S&P 500 Over 10 Years. Now AI Is Changing Everything
TradingView
·
4 hours ago
ETFs to Benefit as Nasdaq's Breakthrough Still Matters
FOREX.com
·
4 hours ago
Dow Jones forecast: Stocks extend drop amid surging oil and elevated yields
BigGo Finance
·
4 hours ago
Deutsche Bank: S&P 500 Q3 Earnings Growth Expected to Hold at Record 34%; Bullish on Year-End Rally
Profile
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
About GlobeImmune Inc
CEO-
Employees22
FoundedJan 1, 1995
HeadquartersLouisville, Colorado, United States
SectorBiotechnology
Websiteglobeimmune.com